After hours: November 13 at 6:47 PM EST Loading Chart for PI ...

You could lose all of your capital. As one of the first projects to get involved with the mobile crypto mining craze, many investors are looking for a Pi Network price prediction to see whether the ...

The company missed on both the topline and bottom line, the analyst tells investors. Additionally, Syfovre and Empaveli came short of expectations, with Syfovre’s launch facing headwinds due to ...

The US regulator has cleared the company’s complement C3 inhibitor pegcetacoplan as an intravitreal injection called Syfovre for GA, which affects more than 5 million people worldwide ...

and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Apellis Pharmaceuticals in a research note ...

If approved, it could become a rival to Apellis Pharma’s Syfovre (pegcetacoplan), which was the first drug cleared to treat geographic atrophy in the US in February. Both drugs are complement ...

Apellis Pharma (APLS) stock experienced a sharp pre-market decline following news that it anticipates a negative opinion from a European regulator on Pegcetacoplan at ...

PI Industries Ltd., incorporated in the year 1946, is a Large Cap company (having a market cap of Rs 69,015.05 Crore) operating in Pesticides/Agro Chemicals sector. PI Industries Ltd. key ...

There is a great need for more effective treatments for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to reduce individual and societal burdens.Clinicians currently have ...